Quest Diagnostics sells OralDNA labs to Access Genetics Quest Diagnostics announced that it has sold substantially all of the assets of its OralDNA(R) Labs salivary-diagnostics business to Access Genetics, a clinical laboratory with advanced molecular diagnostics test development and information technology capabilities. Terms of the transaction were not disclosed.
Quest Diagnostics downgraded to Underperform from Market Perform at Wells Fargo Wells Fargo downgraded Quest Diagnostics (DGX) to its sell-equivalent Underperform rating saying the charges associated with the company's Invigorate savings initiative should not be viewed as one-time by investors. Wells thinks the initiative will need to be ongoing as Quest's margins are declining. It keeps a $60-$65 price target range for shares. The diagnostic testing company closed yesterday up 52c to $71.09. Quest’s main competitor is LabCorp (LH).